目的 探讨氨磷汀联合多西他赛和卡铂治疗卵巢癌的临床疗效。方法 选取2012年2月—2016年2月在南阳市中心医院进行治疗的卵巢癌患者80例，随机分为对照组（40例）和治疗组（40例）。对照组静脉滴注多西他赛注射液，75 mg/m²加入500 mL生理盐水，同时静脉滴注注射用卡铂，300~400 mg/m²加入500 mL生理盐水，1次/28 d；治疗组在对照组的基础上于化疗前30 min静脉滴注注射用氨磷汀，500~600 mg/m²加入500 mL生理盐水，15 min滴完，1次/28 d。两组患者均治疗3次。观察两组患者临床疗效，比较治疗前后两组患者肿瘤标志物水平、QLQ-C30功能领域评分和不良反应情况。结果 治疗后，对照组临床有效率（ORR）和疾病控制率（CBR）分别为52.50%、82.50%，均显著低于治疗组的57.50%、87.50%，两组比较差异具有统计学意义（P < 0.05）。治疗后两组患者血清癌胚抗原（CEA）、糖蛋白125（CA125）、糖蛋白199（CA199）和糖蛋白153（CA153）均显著降低，同组治疗前后比较差异具有统计学意义（P < 0.05）。治疗后，两组患者QLQ-C30功能领域评分明显升高（P < 0.05），且治疗组QLQ-C30功能领域各评分比对照组升高更显著（P < 0.05）。治疗期间，对照组不良反应发生率为47.50%，明显高于治疗组的20.00%，两组比较差异具有统计学意义（P < 0.05）。结论 氨磷汀联合多西他赛和卡铂治疗卵巢癌可有效降低化疗毒副作用，改善患者生活质量，具有一定的临床推广应用价值。

Objective To evaluate the efficacy of amifostine combined with docetaxel and carboplatin in treatment of ovarian cancer. Methods Patients (80 cases) with ovarian cancer in Nanyang City Central Hospital from February 2012 to February 2016 were randomly divided into control (40 cases) and treatment (40 cases) groups. Patients in the control group were iv administered with Docetaxel Injection, 75 mg/m² added into normal saline 500 mL, at the same time they were iv administered with Carboplatin for injection, 300 — 400 mg/m² added into normal saline 500 mL, once every 28 d. Patients in the treatment group were iv administered with Amifostine for injection on the basis of the control group 30 min before chemotherapy, 500 — 600 mg/m² added into normal saline 50 mL, dripped in 15 min, once every 28 d. Patients in two groups were treated for 3 times. After treatment, the clinical efficacy was evaluated, and the tumor markers, QLQ-C30 scores and adverse reactions in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 52.50% and 82.50%, which were significantly lower than 57.50% and 87.50% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the CA125, CA199, CA153, and CEA levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the QLQ-C30 functional scores in two groups were significantly increased (P < 0.05), and QLQ-C30 functional scores in the treatment group were significantly higher than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 47.50%, which was significantly higher than 20.00% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Amifostine combined with docetaxel and carboplatin can effectively reduce the chemotherapy side effect and improve the quality of life in treatment of ovarian cancer, which has a certain clinical application value.